<DOC>
	<DOCNO>NCT01002872</DOCNO>
	<brief_summary>The aim study assess effect drug lanthanum carbonate ( phosphorus binder drug ) c-terminal FGF23 level patient Chronic Kidney Disease ( CKD ) . Targeting FGF23 measurement CKD patient may impact progression kidney disease patient mortality .</brief_summary>
	<brief_title>The Effect Lanthanum Carbonate Fibroblast Growth Factor 23 ( FGF23 ) Chronic Kidney Disease</brief_title>
	<detailed_description>This double blind randomize placebo control pilot study . Subjects Chronic Kidney Disease ( CKD ) stag 3-5 undergoing renal replacement therapy start phosphate binder randomize either lanthanum carbonate 1500 mg daily placebo 60 day treatment period . Patient dos increase maximum dose 3000 mg serum phosphate great 5.5 mg/dL .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Males nonpregnant female age 18 year age older Estimated GFR 1560 ml/min/1.73m Serum phosphate &gt; 3.5 mg/dL FGF2 &gt; 100RU/mL Corrected serum clacium &gt; 8.0mg/dL Current use phosphate binder Corrected serum calcium &lt; 8.0mg/dL Current use prescriptionbased vitamin D therapy Acute kidney injury last 3 month Significant GI disorder History allergic reaction sensitivity lanthanum carbonate History non compliance visit medication preclude study compliance opinion investigator Pregnant able become pregnant unwilling use birth control method consider reliable principal investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>FGF23</keyword>
	<keyword>CKD</keyword>
	<keyword>Fosrenol</keyword>
	<keyword>Hyperphosphatemia</keyword>
</DOC>